Business
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines.
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)","length":196,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, April 15, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines.","length":517,"tagName":"p"},{"type":"image","alt":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WGIrWF_9jgkFNz.d57uEvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2595086/Rein_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The manuscript, titled "Caveolin Scaffolding Domain (CSD) Peptide LTI-2355 Modulates the Phagocytic and Synthetic Activity of Lung-Derived Myeloid Cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)," describes the effects of caveolin scaffolding domain (CSD) peptide LTI-2355 on the immune and synthetic properties of human lung-derived macrophages and other myeloid cells isolated from lung explant tissue of donor lungs, as well as IPF and PASC-F lung explant tissue. LTI-2355 is a soluble and proteolysis-resistant 13-mer CSD peptide with anti-fibrotic properties that has been used in several preclinical models of fibrosis. In the present study, LTI-2355 improved the phagocytic (i.e., anti-infective) activity of both IPF and PASC-F myeloid cells compared with control peptide-treated cells, and this imp...